BioNxt Solutions Set to Receive European Patent for Drug Delivery System

BioNxt Solutions Inc., based in Vancouver, has received formal notice from the European Patent Office (EPO) of their intention to grant the company's core patent. This patent covers a sublingual delivery system for anticancer drugs, targeting autoimmune neurodegenerative diseases. The news marks a significant milestone for BioNxt, particularly regarding their lead product, BNT23001, a sublingual formulation of Cladribine aimed at treating multiple sclerosis.

CEO Hugh Rogers expressed that the confirmation of this intellectual property is a crucial development, anticipating the patent's publication in the coming weeks. This will allow the company to proceed confidently with their upcoming BNT23001 bioequivalence study in Europe. BioNxt is also advancing the nationalization process of this patent across several key regions, including Australia, Canada, New Zealand, the USA, and Japan, which are vital for the company's commercial plans.